Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$52.3M |
| 2 |
Exelon
EXC
|
+$51.9M |
| 3 |
Linde
LIN
|
+$48.3M |
| 4 |
Advanced Micro Devices
AMD
|
+$41.5M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$39.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$251M |
| 2 |
Microsoft
MSFT
|
+$235M |
| 3 |
Amazon
AMZN
|
+$226M |
| 4 |
CoStar Group
CSGP
|
+$103M |
| 5 |
AerCap
AER
|
+$82.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.96% |
| 2 | Industrials | 12.92% |
| 3 | Consumer Discretionary | 9.79% |
| 4 | Financials | 9.27% |
| 5 | Energy | 7.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Toro Company
TTC
$9.5B
| $351K | ﹤0.01% |
4,105
-23,762
| -85% | -$2.21M |
|
1702
United Microelectronic
UMC
$49.7B
| $351K | ﹤0.01% |
38,525
-33,371
| -46% | -$331K |
|
1703
Codexis
CDXS
$185M
| $350K | ﹤0.01% |
+16,957
| New | +$351K |
|
1704
Ecopetrol
EC
$35B
| $349K | ﹤0.01% |
18,758
+3,066
| +20% | +$48.3K |
|
1705
Yum China
YUMC
$16.4B
| $349K | ﹤0.01% |
8,403
-119,012
| -93% | -$5.61M |
|
1706
Q2 Holdings
QTWO
$3.92B
| $348K | ﹤0.01% |
+5,650
| New | +$362K |
|
1707
The Beachbody Company
BODI
$45.5M
| $347K | ﹤0.01% |
3,060
+2,663
| +671% | +$271K |
|
1708
Vital Farms
VITL
$471M
| $346K | ﹤0.01% |
27,971
+3,225
| +13% | +$48.4K |
|
1709
Vivid Seats
SEAT
$80.8M
| $344K | ﹤0.01% |
+1,555
| New | +$331K |
|
|
NVTA
1710
DELISTED
Invitae Corporation
NVTA
| $344K | ﹤0.01% |
+43,109
| New | +$434K |
|
1711
Loop Industries
LOOP
$27.7M
| $343K | ﹤0.01% |
+38,599
| New | +$323K |
|
1712
Spire Global
SPIR
$547M
| $343K | ﹤0.01% |
20,415
+18,433
| +930% | +$360K |
|
|
HHLA
1713
DELISTED
HH&L Acquisition Co.
HHLA
| $343K | ﹤0.01% |
35,000
| – | – |
|
|
MOMO
1714
Hello Group
MOMO
$838M
| $342K | ﹤0.01% |
+59,117
| New | +$513K |
|
1715
Syndax Pharmaceuticals
SNDX
$1.79B
| $342K | ﹤0.01% |
+19,673
| New | +$331K |
|
|
LTCH
1716
DELISTED
Latch, Inc. Common Stock
LTCH
| $342K | ﹤0.01% |
80,087
+49,031
| +158% | +$256K |
|
1717
PagerDuty
PD
$938M
| $341K | ﹤0.01% |
9,977
+2,302
| +30% | +$74K |
|
|
ALEX
1718
DELISTED
Alexander & Baldwin
ALEX
| $340K | ﹤0.01% |
+14,661
| New | +$338K |
|
1719
Leidos
LDOS
$17.3B
| $339K | ﹤0.01% |
3,139
-15,975
| -84% | -$1.54M |
|
1720
Tower Semiconductor
TSEM
$23.9B
| $339K | ﹤0.01% |
7,014
-9,972
| -59% | -$421K |
|
1721
iShares US Healthcare ETF
IYH
$3.84B
| $338K | ﹤0.01% |
+5,850
| New | +$327K |
|
1722
Redwire
RDW
$2.83B
| $337K | ﹤0.01% |
+39,791
| New | +$243K |
|
|
VRAY
1723
DELISTED
ViewRay, Inc.
VRAY
| $336K | ﹤0.01% |
85,763
-1,068
| -1% | -$4.55K |
|
|
BGRY
1724
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $335K | ﹤0.01% |
+116,195
| New | +$414K |
|
|
BLUE
1725
DELISTED
bluebird bio
BLUE
| $334K | ﹤0.01% |
+3,445
| New | +$455K |
|
Similar funds
Michael Gelband's Q1 2022 Portfolio in Review
As of Q1 2022, Michael Gelband held 2,902 positions worth $7.91B, down 18% from $9.67B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Michael Gelband withdrew a net $1.37B in Q1 2022, closing 758 positions and reducing 576 holdings. Its most notable exit was CoStar Group, an estimated $103M position sold in full.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Michael Gelband opened a new position in Linde worth $49.9M.
- Michael Gelband's largest Q1 2022 buy was Linde: 156,289 shares worth $49.9M.
- Michael Gelband added most to ExxonMobil in Q1 2022, an estimated $52.3M increase.
- Michael Gelband's biggest Q1 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $251M.
- Michael Gelband fully exited CoStar Group in Q1 2022, selling an estimated $103M.
- Michael Gelband's ten largest holdings make up 11% of its $7.91B portfolio in Q1 2022.
- Michael Gelband opened 788 new positions and closed 758 in Q1 2022.
- Michael Gelband's portfolio value fell 18% quarter-over-quarter to $7.91B.
Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.